Published in Dig Dis Sci on September 12, 2014
Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction. Inflammopharmacology (2015) 0.76
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol (2016) 0.76
Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health (1992) 20.06
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (2002) 4.97
Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology (2000) 4.74
Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin (2012) 4.13
Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology (2007) 3.94
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50
A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43
Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 2.43
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care (2005) 2.28
Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res (2001) 2.01
The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology (1995) 1.86
Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2002) 1.79
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med (2006) 1.48
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev (1996) 1.39
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology (2002) 1.36
Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol (2011) 1.34
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res (2006) 1.32
Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 1.29
Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res (2009) 1.13
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
The prevalence of and risk factors for Barrett's esophagus in a Korean population: A nationwide multicenter prospective study. J Clin Gastroenterol (2009) 1.02
A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis (2004) 1.00
Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer (2011) 1.00
Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc (2006) 0.94
Regular aspirin use and esophageal cancer risk. Int J Cancer (2006) 0.92
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Dis Esophagus (2010) 0.86
Frequency and risk factors for Barrett's esophagus in Taiwanese patients: a prospective study in a tertiary referral center. Dig Dis Sci (2009) 0.82
Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus. World J Gastrointest Pharmacol Ther (2014) 0.80
Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative. Circ Cardiovasc Qual Outcomes (2014) 0.80
Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf (2014) 0.78
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol (2012) 0.77
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA (2013) 4.67
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst (2007) 3.80
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis (2005) 2.28
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med (2013) 2.15
Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med (2014) 2.05
Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol (2011) 1.78
Chronic kidney disease and risk of renal cell carcinoma: differences by race. Epidemiology (2015) 1.78
Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol (2004) 1.72
Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med (2014) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol (2012) 1.65
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.63
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc (2002) 1.54
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer (2002) 1.48
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med (2008) 1.38
Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol (2012) 1.30
Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology (2012) 1.28
Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst (2013) 1.25
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. Gastrointest Endosc (2012) 1.23
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 1.22
Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology (2008) 1.19
Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut (2011) 1.18
Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci (2009) 1.17
Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med (2016) 1.10
Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus. Nutr Res Rev (2010) 1.05
Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol (2007) 1.04
Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus. Am J Gastroenterol (2008) 1.04
Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am J Gastroenterol (2007) 1.03
Dietary patterns and the risk of Barrett's esophagus. Am J Epidemiol (2008) 1.03
Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer (2010) 1.03
Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol (2011) 1.01
Cigarette smoking and the risk of Barrett's esophagus. Cancer Causes Control (2008) 0.97
Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol (2013) 0.95
The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol (2012) 0.95
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.94
Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr Cancer (2009) 0.92
Colorectal-cancer screening--coming of age. N Engl J Med (2013) 0.89
The road ahead: what if gastroenterologists were accountable for preventing colorectal cancer? Clin Gastroenterol Hepatol (2013) 0.87
Dietary fiber and the risk of precancerous lesions and cancer of the esophagus: a systematic review and meta-analysis. Nutr Rev (2013) 0.87
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 0.84
Approaches for classifying the indications for colonoscopy using detailed clinical data. BMC Cancer (2014) 0.83
Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. J Med Screen (2013) 0.78
Food, the immune system, and the gastrointestinal tract. Gastroenterology (2015) 0.78
Understanding cancer incidence in Barrett's esophagus: light at the end of the tunnel. J Natl Cancer Inst (2011) 0.78
Barrett's esophagus: who should receive ablation and how can we get the best results? Gastroenterology (2012) 0.76
Can You Stop Surveillance After Radiofrequency Ablation of Barrett's Esophagus? A Glass Half Full. Gastroenterology (2013) 0.76
Vertical transmission of hepatitis B virus--in response. Ann Intern Med (2014) 0.75
The authors respond. Epidemiology (2015) 0.75
Cancer incidence in Barrett's esophagus: does it really matter, and who's counting anyway? Gastrointest Endosc (2008) 0.75
Racial/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems. Medicine (Baltimore) (2017) 0.75
Chemoprevention in Barrett's esophagus: are we there yet, are we there yet...? Clin Gastroenterol Hepatol (2009) 0.75
How should we select health professionals for studies? Outcomes Manag (2003) 0.75
The 75(th) Diamond Anniversary of Gastroenterology: 1943-2018. Gastroenterology (2017) 0.75
Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing. J Clin Gastroenterol (2017) 0.75